CONTENTS: APRIL 2003

By BIO-IT World

Features

Beyond the Blueprint 
How will the wealth of data emanating from the human genome and allied technologies impact research on health and disease?
By Malorye Branca
 

Target Elimination 
SPECIAL REPORT: Resolving Bottlenecks, Part II
Industry and FDA scientists turn to databases, applications software, and laboratory chips to move the safest, most effective molecules into clinical trials. By Mark D. Uehling
 

Strategic Insights 
· Regulatory Compliance
· Easing the Pain of Part 11
· Part 11: The FDA's New View
· Rising to the Regulatory Challenge
· E-Sourcing: Covering the Regulatory Bases

News·Analysis 
EDC Shreds Paper Trails
Debating DNA in Monterey
Neuroscientists Have Better Tools on the Brain
Hopkins Takes IBM to Heart
From Field to Streaming Data
Genomic Services Sector Heats Up
Kinder, Gentler FDA in the Making?
Nanotech Sprouts in the Garden State


Bio-IT World Conference & Expo Highlights:

Stephen Friend Sees Novel Uses of Gene Chips
IBM’s Kovac on Information-Based Medicine
Francis Collins Nixes Post-Genomic Era
Best of Show Awards



Horizons

James Watson
Honest Jim Watson remains as charming, humorous, obstinate, and outrageous as ever. 

Get into the Groove
Scientists strike a chord with music based on the building blocks of DNA. 

Homeland Security 
The bio-IT community has a unique opportunity to contribute to national biodefense. 

Columns & Departments

First Base | Kevin Davies
The world celebrates the golden anniversary of the double helix.


Nothing Ventured... | Michael A. Greeley
As biotech business models evolve, the question remains: Which will survive? 


Fully Equipped | By Robert M. Frederickson
Protein chips seek to do for protein expression profiling what DNA chips did for RNA expression. 


The Dodge Retort | John Dodge
Complaints aside, EDC has made its mark. All it needs now is a big boot.


New Products
MEMS the word for Protiveris prototype · RLX doubles up with dual-processor blade server · EMC debuts high-end storage systems 


Letters
White Papers & Special Reports

thomson reuters image
Biomarkers: An Indispensible Addition to the Drug Development Toolkit
Examining the Potential of Biomarkers
Sponsored by Thomson Reuters

Biomarkers are becoming an essential part of clinical development. In this white paper, Thomson Reuters provides insight from experts in industry and academia, and explores the role of biomarkers as evaluative tools in improving clinical research and the challenges this presents.

Discover the potential of biomarkers to:

  • Improve decision making
  • Accelerate drug development
  • Reduce development costs


BlueArc_Scientific Data
Scientific Data Lifecycle Management: Preparing for Storage in an Uncertain Future
Sponsored by BlueArc

Managing vast and overwhelming streams of gene sequencing data today requires ultra-high performance systems and processes. With continued rapid advancement and improvements in gene sequencing, expect tomorrow’s instruments to output quantities of genomic information that will dwarf current levels. Help your organization maintain data control and prepare for the future of sequencing through this informative paper that discusses:

  • The information technology challenges of gene sequencing
  • “Intelligent” methods for data management and customization
  • System survival tips... Deciding what data to keep or delete
  • New tools to keep scientists ahead of impending data torrents


SAS Managed image
Managed Innovation, Assured Compliance
Developing, executing and managing the transformation, analysis and submission of clinical research data with SAS® Drug Development
Sponsored by SAS
Get better products to market faster. Download this white paper to discover the top ten challenges facing life science executives and how to overcome them. See how SAS Drug Development transforms clinical data into true innovation.


Life Science Webcasts & Podcasts

Presented by Trade Commission of Spain

Spain Biotech: An Engine for Economic Change 

TCS podcastDiscover how Spain is focusing on biotechnology to be an engine for economic change through gradual internationalization, development and technology transfer.

Regional governments are actively investing in public and private biology research and promoting the creation of knowledge-based companies. Spain’s human capital combined with aggressive investment in biotech research and infrastructure has led to the creation of bio-clusters.

Today, there are nearly 700 Spanish companies engaged in biotechnology, with almost 50 percent growth in funding devoted to research. In fact, spending on internal R & D in biotechnology has grown 46 percent and is close to 300 million Euros.

Access the podcast 

 



More Podcasts

Job Openings

saic_logo

MANAGER, SCIENTIFIC COMPUTING & PROGRAMMING
(Bioinformatics Manager)
SAIC-Frederick, Inc has an exciting opportunity for a Manager, Scientific Computing & Programming - Core Genoytyping Facility in Gaithersburg, Maryland.  In this role, you will lead the Bioinformatics & Analysis Group.
Master’s or equivalent required.  PhD preferred. Six years experience in development of scientific programs in high-performance computing environment including five years supporting scientific research in computational chemistry, biology, or genetics, & two years supervisory experience.  View complete job posting & apply: www.saic-frederick.com. Position #146945.

For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.